AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 281 min read$GOSS

Gossamer Bio, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that the Company has regained…

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for con

Original reporting
SEC EDGAR 8-K
Published Sep 28, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$GOSS
Bullish
high confidence
Mentioned
$GOSS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GOSSBullishLow
01

Why it matters

The 8‑K filing confirms the company now meets the bid‑price requirement, removing a delisting threat and possibly stabilizing the share price.

02

Market read

A primary disclosure of compliance restoration; relevant for traders holding or watching GOSS, with limited broader market impact.

03

What to watch

Potential dilution from the reverse split and any lingering liquidity concerns.

Relevance 6/10Novelty 7/10Timing: today

Background

Gossamer Bio (NASDAQ: GOSS) previously fell out of compliance with Nasdaq's $1 minimum bid price rule, prompting a 1‑for‑80 reverse split on September 10, 2026.

Company-level read

Ticker impact

$GOSSBullishHigh confidence
Context

Gossamer Bio disclosed it regained Nasdaq minimum bid price compliance after a 1‑for‑80 reverse split, closing the compliance issue.

Expected impact

likely modest upside as investors view the compliance fix favorably

Evidence & confidence

The filing is the first public notice of compliance; no further material events are mentioned.

Market effects

Sector

Shows Nasdaq's enforcement of bid‑price rules, may prompt other low‑price stocks to consider reverse splits.

Regional

Limited to U.S. micro‑cap biotech segment.

Global

Minimal; primarily a company‑specific compliance update.

Counterpoint

What could challenge this read

The compliance fix may be seen as a cosmetic move; underlying business fundamentals remain unchanged.

Key entities

  • company
    Gossamer Bio, Inc.

    Biotech firm listed on Nasdaq, ticker GOSS.

  • regulator
    Nasdaq Listing Qualifications Department

    Nasdaq unit that monitors compliance with listing standards.

Read at source← All news

Related articles

OCT 13
$GOSSMed

Chardan initiates Gossamer Bio stock with buy on PAH therapy potential

Chardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.

investing.com2 min
SEP 23
$GOSSMedAI 8/10

Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging

Gossamer Bio (GOSS) filed an NDA for seralutinib, its treatment for pulmonary arterial hypertension. The submission is based on clinical data from the PROSERA and TORREY studies, though the PROSERA trial did not meet its primary endpoint. GOSS trades at a P/S ratio of 0.62, below its historical median and industry averages, reflecting market skepticism. The company has a GF Score of 22/100, indicating significant financial and operational challenges.

gurufocus.com2 min
SEP 23
$GOSSHighAI 8/10

Gossamer Bio stock rises on FDA filing for PAH drug

Gossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.

investing.com2 min
SEP 23
$GOSSMedAI 8/10

Gossamer Bio, Inc. announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the…

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

SEC EDGAR 8-K2 min